HCC Clinical Trials 2022
Hepatocellular Carcinoma studies recruiting patients for novel treatments. Filter by phase, distance, and inclusion criteria to find your perfect hcc clinical trial in 2022.
Condition
Hepatocellular Carcinoma
Location
Distance
10 miles
50 miles
Any
Age
Search
Clinical Trials
HCC Clinical Trials 2022
Phase-Based Estimates
1
Effectiveness
2
Safety
Tremelimumab
for Carcinoma
Toronto, Canada
18+
All Sexes
Phase 2
Waitlist Available
Grade I
Toronto, Canada
18+
All Sexes
Hepatocellular Carcinoma (HCC) is the third most common cause of death from cancer world wide and the incidence is rising globally. Despite surgical resection in appropriate patients, many patients recur. The results of the IMbrave150 study have established PD-L1 inhibition in combination with VEGF inhibition as a new standard of care highlighting the role of immune checkpoint inhibition in advanced HCC. In addition, the combination of Tremelimumab and Durvalumab has demonstrated efficacy in advanced HCC; the HIMALAYA trial has now completed accrual in treatment naïve patients with advanced HCC. Furthermore the earlier use of immune checkpoint inhibitors in this disease are being explored with adjuvant combination strategies, including the EMERALD-2 trial (NCT03847428). Neoadjuvant treatment in HCC allows for delivery of treatment pre surgery and may enhance pathological responses and improve outcomes. The delivery of combination CTLA-4 and PD-L1 inhibition has demonstrated efficacy in other tumour types in the neoadjuvant setting where the impact on the tumour microenvironment has also been evaluated. The safety and feasibility of Durvalumab and Tremelimumab in resectable HCC has yet to be established. Hypotheses Pre-operative (pre-op) Durvalumab and Tremelimumab treatment is safe and feasible in pre surgical setting for upfront resectable HCC The combination of Durvalumab and Tremelimumab pre-op will result in changes in immune and molecular characteristics within the tumour microenvironment. Overall Study Design This is a phase II, open-label multi-centre study to assess safety of Durvalumab and Tremelimumab treatment in pre-op setting for upfront resectable HCC, followed by adjuvant Durvalumab. 28 patients are expected to enrol at three sites. Patients will receive pre-op: 1 dose Tremelimumab (300mg) (T300) with Durvalumab (1500mg) at cycle 1 and 1 further cycle of Durvalumab (1500mg) only. Post-surgical resection, adjuvant therapy will consist of Durvalumab Q4W for up to a maximum of 12 months in total or 13 cycles of Durvalumab (11 cycles post op). All participants will be treated until progressive disease or unacceptable toxicity or withdrawal of consent or another discontinuation criterion is met. All participants will be followed for survival until the end of study. No dose reductions of Tremelimumab and Durvalumab will be allowed. Statistics The primary objective of this study is to assess safety of pre-op treatment with Durvalumab and Tremelimumab. For safety, with the null proportion of patients who discontinue treatment due to AEs, imAEs or SAE is 30% versus the alternative proportion is 10% or less than 10%, a sample size of 28 provides 80% power to detect the proportion difference with a two-sided alpha level of 0.1. The sample size estimate is based on the two-sided exact test for binomial proportion considering Binomial Enumeration method.
Phase-Based Estimates
1
Effectiveness
1
Safety
Piflufolastat F18
for Breast Cancer
Houston, TX
18+
All Sexes
Phase < 1
Waitlist Available
Metastatic
Houston, TX
18+
All Sexes
To learn if piflufolastat F18 can be used in imaging scans for patients with breast cancer, HCC, or pancreatic cancer
Phase-Based Estimates
1
Effectiveness
2
Safety
Tislelizumab
for Carcinoma, Hepatocellular
New Brunswick, NJ
18+
All Sexes
Phase 2
Waitlist Available
Locally Advanced
New Brunswick, NJ
18+
All Sexes
The investigators hypothesize that the addition of Tislelizumab after definitive local therapy for locally advanced inoperable Hepatocellular carcinoma (HCC) will synergize with local therapy as well as treat micro metastatic disease and improve one year progression-free survival rates for participants and optimize local control.
Phase-Based Estimates
1
Effectiveness
2
Safety
Bevacizumab
for Hepatocellular Carcinoma
Duarte, CA
18+
All Sexes
Phase 2
Recruiting
Locally Advanced
Duarte, CA
18+
All Sexes
This is a randomized Phase 2 trial designed to evaluate the efficacy and safety of SRF388 in combination with atezolizumab plus bevacizumab compared to placebo (inactive substance) in combination with atezolizumab plus bevacizumab in patients with first-line advanced or metastatic HCC.
Phase-Based Estimates
1
Effectiveness
1
Safety
E7386
for Colorectal Cancer
Los Angeles, CA
18+
All Sexes
Phase 1 & 2
Recruiting
Locally Advanced
Los Angeles, CA
18+
All Sexes
The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386 in combination with pembrolizumab in participants with previously treated selected solid tumors, and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with pembrolizumab. The Phase 2 part of this study is conducted to assess the objective response rate (ORR) of E7386 in combination with pembrolizumab in participants with previously treated selected solid tumors (melanoma, colorectal cancer [CRC], hepatocellular carcinoma [HCC]) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
Phase-Based Estimates
1
Effectiveness
1
Safety
Cyclophosphamide
for Cancer
Hackensack, NJ
18+
All Sexes
Phase 1
Recruiting
Locally Advanced
Hackensack, NJ
18+
All Sexes
This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
Phase-Based Estimates
1
Effectiveness
1
Safety
INCA00186
for Oral Squamous Cell Carcinoma
Houston, TX
18+
All Sexes
Phase 1
Recruiting
Locally Advanced
Houston, TX
18+
All Sexes
This study is evaluating whether a drug called INCB106385 can be used to treat cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Belzutifan
for Carcinoma, Hepatocellular
Houston, TX
18+
All Sexes
Phase 2
Recruiting
Locally Advanced
Houston, TX
18+
All Sexes
This study is evaluating whether a combination of belzutifan and pembrolizumab and lenvatinib is safe and effective in multiple solid tumors.
Phase-Based Estimates
1
Effectiveness
2
Safety
Fluorine-18 Fluorocholine
for Carcinoma, Hepatocellular
Honolulu, HI
18+
All Sexes
Phase 2
Recruiting
Locally Advanced
Honolulu, HI
18+
All Sexes
This study is evaluating whether a PET scan can predict whether a patient will respond to ICI therapy.
Phase-Based Estimates
1
Effectiveness
1
Safety
CT-0508
for Inflammatory Breast Neoplasms
Nashville, TN
18+
All Sexes
Phase 1
Recruiting
Metastatic
Nashville, TN
18+
All Sexes
This study is evaluating whether a type of white blood cell called a macrophage may help treat certain types of cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Pembrolizumab
for Carcinoma
Houston, TX
18+
All Sexes
Phase 1
Recruiting
Locally Advanced
Houston, TX
18+
All Sexes
This study is evaluating whether a new drug may help treat cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
RO7119929
for Carcinoma, Hepatocellular
Washington, United States
18+
All Sexes
Phase 1
Waitlist Available
Locally Advanced
Washington, United States
18+
All Sexes
This study is evaluating whether a drug may help treat liver cancer.
Phase-Based Estimates
2
Effectiveness
3
Safety
Lenvatinib
for Carcinoma, Hepatocellular
Tampa, FL
18+
All Sexes
Phase 3
Recruiting
Metastatic
Tampa, FL
18+
All Sexes
This study is evaluating whether a combination of two drugs may help treat liver cancer.
Phase-Based Estimates
2
Effectiveness
3
Safety
Atezolizumab
for Carcinoma, Hepatocellular
Phoenix, AZ
18+
All Sexes
Phase 3
Waitlist Available
High Risk
Phoenix, AZ
18+
All Sexes
This study is evaluating whether a combination of two drugs may help prevent the return of cancer in patients who have had their cancer removed.
Phase-Based Estimates
1
Effectiveness
1
Safety
ABX196
for Carcinoma, Hepatocellular
Houston, TX
18+
All Sexes
Phase 1 & 2
Recruiting
1 Prior Treatment
Houston, TX
18+
All Sexes
This study is evaluating whether a combination of two drugs may help treat liver cancer.
Phase-Based Estimates
2
Effectiveness
3
Safety
Lenvatinib
for Carcinoma, Hepatocellular
Miami, FL
18+
All Sexes
Phase 3
Waitlist Available
Locally Advanced
Miami, FL
18+
All Sexes
This study is evaluating whether a new drug combination is better than a standard drug combination for treating liver cancer.
Phase-Based Estimates
2
Effectiveness
3
Safety
Simvastatin 40mg
for Liver Cirrhosis
Louisville, KY
18+
All Sexes
Phase 3
Recruiting
High Risk
Louisville, KY
18+
All Sexes
This study is evaluating whether a common cholesterol lowering drug may help prevent liver failure in individuals with cirrhosis.
Phase-Based Estimates
1
Effectiveness
1
Safety
Toripalimab, Recombinant Humanized Anti-PD-1 Monoclonal Antibody
for Cancer
Providence, RI
18+
All Sexes
Phase 1
Waitlist Available
Locally Advanced
Providence, RI
18+
All Sexes
The primary objective is to assess the safety and tolerability of Toripalimab in subjects with various advanced malignancies and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of Toripalimab, 2) evaluate antitumor activity of Toripalimab; 3) determine the immunogenicity of Toripalimab; 4) evaluate overall survival. The exploratory objectives are to: 1) evaluate biomarkers that may correlate with activity of Toripalimab, 2) evaluate pharmacodynamic effects of Toripalimab on its target receptor, programmed cell death 1 (PD-1), as well as effects on the immune system. 3) evaluate the utility of PD-L1 & additional exploratory markers as biomarkers that could aid in selection of appropriate subjects for TAB001 therapy, and 4) identification of additional biomarkers correlating with response to treatment with TAB001.
Phase-Based Estimates
1
Effectiveness
1
Safety
Pembrolizumab
for Carcinoma, Hepatocellular
Seattle, WA
18+
All Sexes
Phase 1
Waitlist Available
Locally Advanced
Seattle, WA
18+
All Sexes
This study is evaluating whether a combination of drugs can be safely given to people with liver cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Meclizine Oral Tablet
for Carcinoma, Hepatocellular
Houston, TX
18+
All Sexes
Phase 1
Recruiting
Houston, TX
18+
All Sexes
This study is evaluating whether meclizine can be used to treat hepatocellular carcinoma.
Phase-Based Estimates
2
Effectiveness
3
Safety
Proton Therapy (Radiation Therapy)
for Carcinoma, Hepatocellular
West Chester, OH
18+
All Sexes
Phase 3
Recruiting
1 Prior Treatment
West Chester, OH
18+
All Sexes
This study is evaluating whether a type of radiation therapy may help treat liver cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Lenvatinib
for Carcinoma, Hepatocellular
New York, NY
18+
All Sexes
Phase 1
Waitlist Available
Locally Advanced
New York, NY
18+
All Sexes
This study is evaluating whether a drug combination can be used to treat liver cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
GLYCAR T Cells
for Carcinoma
Houston, TX
18+
All Sexes
Phase 1
Waitlist Available
Metastatic
Houston, TX
18+
All Sexes
This study enrolls patients who have a type of cancer that arises from the liver called hepatocellular carcinoma. The cancer has come back, has not gone away after standard treatment, has spread outside of the liver or the patient cannot receive standard treatment. This research study uses special immune system cells called GLYCAR T cells, a new experimental treatment. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Antibodies are types of proteins that protect the body from infectious diseases and possibly cancer. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including cells infected with viruses and tumor cells. Both antibodies and T cells have been used to treat patients with cancers. They have shown promise, but have not been strong enough to cure most patients. Investigators have found from previous research that they can put a new gene into T cells that will make them recognize cancer cells and kill them. In preclinical studies, the investigators made several genes called a chimeric antigen receptor (CAR), from an antibody called GC33 that recognizes glypican-3, a protein found on almost all hepatocellular carcinoma cells (GPC3-CAR). This study will test T cells genetically engineered with a GPC3-CAR (GLYCAR T cells) in patients with hepatocellular carcinoma. The GLYCAR T cells are an investigational product not approved by the Food and Drug Administration. The purpose of this study is to find the biggest dose of GLYCAR T cells that is safe, to see how long they last in the body, to learn what the side effects are and to see if the GLYCAR T cells will help people with GPC3-positive hepatocellular carcinoma.
Phase-Based Estimates
1
Effectiveness
1
Safety
Radiation Therapy
for Cholangiocarcinoma
Houston, TX
18+
All Sexes
Phase 1
Recruiting
Locally Advanced
Houston, TX
18+
All Sexes
This study is evaluating whether radiation therapy is safe and effective in treating patients with liver cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Outreach With Patient Education And Patient Navigation Services
for Carcinoma, Hepatocellular
Dallas, TX
18+
All Sexes
Waitlist Available
Dallas, TX
18+
All Sexes
This study is evaluating whether a mailed outreach strategy can increase HCC surveillance among patients with cirrhosis.
Phase-Based Estimates
1
Effectiveness
2
Safety
Yttrium Y 90 Glass Microspheres
for Carcinoma, Hepatocellular
Portland, OR
18+
All Sexes
Phase 2
Waitlist Available
Grade I
Portland, OR
18+
All Sexes
This phase II trial tests whether yttrium Y 90 glass microspheres, atezolizumab, and cabozantinib work to shrink tumors in patients with liver cancer (hepatocellular carcinoma) that cannot be removed by surgery (unresectable) or that has spread to nearby tissue or lymph nodes (locally advanced). Yttrium Y 90 glass microspheres consists of millions of microscopic glass spheres containing yttrium-90, a radioactive substance. Yttrium Y 90 glass microspheres are delivered to the tumor in the liver through a catheter in an artery. Radiation from the Yttrium-90 helps treat the tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The combination of yttrium Y 90 glass microspheres, atezolizumab, and cabozantinib may kill more tumor cells.
Phase-Based Estimates
1
Effectiveness
1
Safety
Atezolizumab
for Carcinoma
Tampa, FL
18+
All Sexes
Phase 1
Recruiting
Locally Advanced
Tampa, FL
18+
All Sexes
This study is evaluating whether a drug called Selinexor can be used to treat advanced Hepatocellular Carcinoma.
Phase-Based Estimates
1
Effectiveness
2
Safety
Bevacizumab
for Carcinoma, Hepatocellular
Chicago, IL
18+
All Sexes
Phase 2
Recruiting
Locally Advanced
Chicago, IL
18+
All Sexes
This study is evaluating whether a combination of two medications may be safe for individuals with liver cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Telatinib
for Carcinoma, Hepatocellular
Los Angeles, CA
18+
All Sexes
Phase 2
Recruiting
Locally Advanced
Los Angeles, CA
18+
All Sexes
This study is evaluating whether a drug may help treat stomach and liver cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
TheraBionic Device
for Carcinoma, Hepatocellular
Chicago, IL
18+
All Sexes
Phase 2
Recruiting
Locally Advanced
Chicago, IL
18+
All Sexes
This study is evaluating whether electromagnetic fields may help treat cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Resin Microspheres Containing Yttrium-90 (Y-90)
for Carcinoma
Winston-Salem, NC
18+
All Sexes
Recruiting
Metastatic
Winston-Salem, NC
18+
All Sexes
This study is evaluating whether SIRT using SIR-Spheres Y-90 resin microspheres is safe and effective for local control of HCC in patients with Barcelona Clinic Liver Cancer (BCLC) stage A, B1, B2,
Phase-Based Estimates
1
Effectiveness
1
Safety
STP705
for Carcinoma, Hepatocellular
Milwaukee, WI
18+
All Sexes
Phase 1
Recruiting
Grade I
Milwaukee, WI
18+
All Sexes
This is an open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of STP705 administered intratumorally in cholangiocarcinoma, hepatocellular carcinoma or liver metastasis in subjects with advanced/metastatic or surgically unresectable solid tumors who are refractory to standard therapy. Goals: To determine the MTD or RP2D of STP705 when administered intratumorally into cholangiocarcinoma, hepatocellular carcinoma, or liver metastasis. To establish the dose of STP705 recommended for future phase 2 studies when administered intratumorally.
Phase-Based Estimates
1
Effectiveness
2
Safety
Atezolizumab
for Carcinoma, Non-Small-Cell Lung
Toronto, Canada
18+
All Sexes
Phase 2
Recruiting
Grade I
Toronto, Canada
18+
All Sexes
This study is evaluating whether a drug called atezolizumab is effective for people with inoperable liver cancer or non-small lung cancer that has spread to the liver.
Phase-Based Estimates
1
Effectiveness
2
Safety
Transarterial Chemoembolization
for Carcinoma, Hepatocellular
Orange, CA
18+
All Sexes
Phase 2
Recruiting
Metastatic
Orange, CA
18+
All Sexes
This study is evaluating whether a drug may help treat liver cancer.
Phase-Based Estimates
3
Effectiveness
3
Safety
Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid
for Carcinoma, Hepatocellular
La Jolla, CA
18+
All Sexes
Phase 4
Recruiting
La Jolla, CA
18+
All Sexes
This study is evaluating whether a new type of MRI scan may be useful for detecting liver cancer.
Phase-Based Estimates
2
Effectiveness
3
Safety
CS1003+Lenvatinib
for Carcinoma
Coronado, CA
18+
All Sexes
Phase 3
Recruiting
Locally Advanced
Coronado, CA
18+
All Sexes
This study is evaluating whether a combination of a drug and a light therapy can improve the survival of people with liver cancer.
Phase-Based Estimates
2
Effectiveness
3
Safety
Ipilimumab
for Carcinoma, Hepatocellular
Dallas, TX
18+
All Sexes
Phase 3
Recruiting
Locally Advanced
Dallas, TX
18+
All Sexes
This study is evaluating whether a combination of two drugs may help treat liver cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
68Ga-PSMA-11 PET/MRI
for Carcinoma, Hepatocellular
Rochester, MN
18+
All Sexes
Phase 1 & 2
Waitlist Available
Rochester, MN
18+
All Sexes
This study is evaluating whether a drug/radiopharmaceutical may be useful in evaluating liver cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Tivozanib
for Carcinoma, Hepatocellular
Duarte, CA
18+
All Sexes
Phase 1 & 2
Recruiting
Locally Advanced
Duarte, CA
18+
All Sexes
This study is evaluating whether a combination of two drugs may help treat liver cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
TBI 302
for Carcinoma, Hepatocellular
Indianapolis, IN
18+
All Sexes
Phase 1
Waitlist Available
Indianapolis, IN
18+
All Sexes
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. TBI 302 is being developed for the treatment of inoperable HCC by intravenous infusion. The objective is to determine the safety and tolerability of TBI 3002.
Phase-Based Estimates
2
Effectiveness
3
Safety
Pembrolizumab
for Carcinoma, Hepatocellular
Louisville, KY
18+
All Sexes
Phase 3
Recruiting
Louisville, KY
18+
All Sexes
This study is evaluating whether a drug may help prevent the recurrence of liver cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Durvalumab
for Carcinoma, Hepatocellular
Baltimore, MD
18+
All Sexes
Phase 2
Recruiting
Newly Diagnosed
Baltimore, MD
18+
All Sexes
This study is evaluating whether a combination of two immunotherapy drugs may help treat liver cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Durvalumab
for Carcinoma, Hepatocellular
Boston, MA
18+
All Sexes
Phase 2
Recruiting
Locally Advanced
Boston, MA
18+
All Sexes
This research study is studying a combination of drugs as a possible treatment for Hepatocellular Carcinoma or Biliary Tract Cancer. The interventions involved in this study are: Durvalumab Tremelimumab Radiation Therapy
Phase-Based Estimates
2
Effectiveness
3
Safety
Atezolizumab
for Carcinoma, Hepatocellular
Montreal, Canada
18+
All Sexes
Phase 3
Waitlist Available
Locally Advanced
Montreal, Canada
18+
All Sexes
This study is evaluating whether a drug called atezolizumab can be used to treat liver cancer.
Phase-Based Estimates
2
Effectiveness
3
Safety
Nivolumab
for Relapse
Edmonton, Canada
18+
All Sexes
Phase 3
Waitlist Available
High Risk
Edmonton, Canada
18+
All Sexes
This study is evaluating whether a drug called nivolumab can improve survival in people with liver cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Sorafenib
for Carcinoma, Hepatocellular
Harrison, NY
18+
All Sexes
Phase 2
Waitlist Available
Locally Advanced
Harrison, NY
18+
All Sexes
This study is evaluating whether a combination of two drugs might have a better effect than either drug alone.
Phase-Based Estimates
1
Effectiveness
1
Safety
Phase I Dose Level -1
for Carcinoma, Hepatocellular
La Jolla, CA
18+
All Sexes
Phase 1
Waitlist Available
La Jolla, CA
18+
All Sexes
The primary objective of this phase I dose escalation study is to determine the maximum tolerated dose of TH-302 when administered with doxorubicin via trans-arterial chemo-embolization (TACE) in patients with hepatocellular carcinoma (HCC) who are not transplant candidates and have unresectable disease. HCC is the second leading cause of worldwide cancer death and is generally incurable without liver transplant. TACE can convert about 40% of these patients to transplant candidates. Additionally, in non-transplant HCC patients, TACE confers statistical improvements in overall survival. Selective HCC arterial catheterization during TACE allows for the delivery of concentrated drugs to the liver tumor but the optimal TACE chemotherapy regimen has not yet been determined. TH-302 is a hypoxia inducible agent that can be activated in the hypoxic environment induced by TACE.
Phase-Based Estimates
1
Effectiveness
2
Safety
Sorafenib
for Carcinoma, Hepatocellular
Newark, NJ
18+
All Sexes
Phase 2
Waitlist Available
Newark, NJ
18+
All Sexes
The purpose of this study is to determine if VT-122 provides a clinical benefit when added to Sorafenib in patients with advanced hepatocellular carcinoma (HCC).
Phase-Based Estimates
1
Effectiveness
2
Safety
Mitomycin-c, Cisplatin
for Carcinoma
Los Angeles, CA
18+
All Sexes
Phase 2
Waitlist Available
Los Angeles, CA
18+
All Sexes
This study is for people with cancer of the liver that cannot be completely removed by surgery. This study involves giving the drugs mitomycin-C and cisplatin, into an artery in the liver. Mitomycin-C is a drug that has been approved by the FDA to treat cancer of the stomach and pancreas. Mitomycin-C is a drug that causes cancer cells to die and prevents them from reproducing. Cisplatin is also a drug that has been approved by the FDA. Cisplatin is approved to treat cancer of the testes, ovaries, lung, esophagus, bladder, head and neck. Cisplatin is a drug that prevents cancer cells from reproducing. The purpose of this study is to see how long it takes subjects' tumor(s) to grow after receiving the study drugs. Another purpose of this study is to look at the side effects of this study therapy and how long subjects survive after receiving it. An additional purpose of this study is to see how well we can predict subjects' response to the study therapy, based on blood and tumor tissue tests. These tests will measure the levels of genes (the cell's blueprint) in subjects' tumors and blood. These genes affect how people's bodies react to the cancer drugs.
Phase-Based Estimates
1
Effectiveness
2
Safety
Regorafenib
for Carcinoma
Milwaukee, WI
18+
All Sexes
Phase 2
Waitlist Available
1 Prior Treatment
Milwaukee, WI
18+
All Sexes
This phase II trial tests whether regorafenib and durvalumab work to shrink tumors in patients with high-risk liver cancer. Regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving regorafenib and durvalumab may work better in treating patients with high-risk liver cancer.
Phase-Based Estimates
3
Effectiveness
3
Safety
Atezolizumab
for Carcinoma
Houston, TX
18+
All Sexes
Phase 4
Waitlist Available
Grade II
Houston, TX
18+
All Sexes
Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are transplant-eligible will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receiving standard of care transarterial chemoembolization (TACE). We hypothesize that atezolizumab and bevacizumab can appropriately bridge patients with HCC beyond MC to transplantation and not increase the risk of 1-year post-transplant rejection.
Phase-Based Estimates
1
Effectiveness
2
Safety
GT90001
for HCC
Duarte, CA
18+
All Sexes
Phase 2
Recruiting
Locally Advanced
Duarte, CA
18+
All Sexes
This is a global phase II, open label study in the subjects with Advanced Hepatocellular Carcinoma (aHCC) who were intolerant or had progressed after or intolerant to first-line Immune Checkpoint Inhibitors (ICI) such as Atezolizumab plus Bevacizumab, or ICI plus Tyrosine Kinase Inhibitor (TKI). Based on published and first-hand experience with the safety and tolerability of both GT90001 and Nivolumab, the proposed dose is GT90001 7 mg/kg in combination with Nivolumab 240 mg, infusion every two weeks. This study will enroll a total of 105 subjects to receive combinational therapy of Nivolumab and GT90001. • Nivolumab 240 mg will first be administered by intravenous infusion over 30 minutes, then 30 minutes later, give intravenous infusion of GT90001 7.0 mg/kg over 60 min, once every two weeks.
Phase-Based Estimates
1
Effectiveness
1
Safety
Hepatic Artery Embolization
for Carcinoma
Rochester, MN
18+
All Sexes
Phase < 1
Recruiting
Rochester, MN
18+
All Sexes
This study is evaluating whether a new imaging agent can be used to detect liver cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Lenvatinib
for Relapse
Scottsdale, AZ
18+
All Sexes
Phase 2
Recruiting
Class II
Scottsdale, AZ
18+
All Sexes
This study is evaluating whether lenvatinib can stop the growth of tumor cells in people with hepatocellular carcinoma that has come back after a liver transplant.
Phase-Based Estimates
1
Effectiveness
1
Safety
CATCH T Cells
for Carcinoma, Hepatocellular
Houston, TX
18+
All Sexes
Phase 1
Recruiting
Grade II
Houston, TX
18+
All Sexes
This study is evaluating whether a surgery which reduces blood flow in a stomach artery leads to significant weightloss.
Phase-Based Estimates
1
Effectiveness
1
Safety
CAR-T Cell
for Carcinoma, Hepatocellular
Bethesda, MD
18+
All Sexes
Phase 1
Recruiting
Grade I
Bethesda, MD
18+
All Sexes
This study is evaluating whether a new treatment for liver cancer is safe.
Phase-Based Estimates
1
Effectiveness
2
Safety
Pembrolizumab/Quavonlimab
for Carcinoma, Hepatocellular
Roanoke, VA
18+
All Sexes
Phase 2
Recruiting
Locally Advanced
Roanoke, VA
18+
All Sexes
This study is evaluating whether a combination of two drugs may help treat liver cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Selective Internal Radiation Therapy
for Carcinoma, Hepatocellular
Ann Arbor, MI
18+
All Sexes
Phase 1
Recruiting
Ann Arbor, MI
18+
All Sexes
This study is evaluating whether a combination of radiation therapy and chemotherapy may be more effective than either treatment alone for individuals with liver cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
ET140203 Autologous T Cell Product
for Carcinoma, Hepatocellular
Westwood, KS
18+
All Sexes
Phase 1 & 2
Recruiting
Class I
Westwood, KS
18+
All Sexes
This study is evaluating whether a type of white blood cell called T-cells may help treat liver cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Cabozantinib
for Carcinoma, Hepatocellular
Dallas, TX
18+
All Sexes
Phase 1 & 2
Recruiting
Grade I
Dallas, TX
18+
All Sexes
This study is evaluating whether cabozantinib may be effective in treating liver cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
Pembrolizumab
for Carcinoma
Cincinnati, OH
< 65
All Sexes
Phase 2
Recruiting
Grade I
Cincinnati, OH
< 65
All Sexes
This study is evaluating whether an immunotherapy drug may help treat liver cancer in children.
Phase-Based Estimates
1
Effectiveness
2
Safety
YIV-906+Sorafenib
for Carcinoma, Hepatocellular
Flushing, NY
18+
All Sexes
Phase 2
Recruiting
Locally Advanced
Flushing, NY
18+
All Sexes
The aim of this study is to compare the efficacy and safety of YIV-906 plus standard-of-care sorafenib versus those of sorafenib alone as a first-line systemic treatment for patients with Hepatitis B (+) associated advanced hepatocellular carcinoma. YIV-906 (PHY906, KD018) is an immune system modulator. Clinical and preclinical research suggests that YIV-906 could act to enhance the body's immune response to fight cancer and increase the anti-tumor activity of sorafenib and protect and repair the gastrointestinal tract by reducing inflammation and promoting tissue regeneration. Inspired by a 1,800-year-old traditional medicine still in use today, YIV-906 is a botanical drug candidate, composed of an extract of four herbs and administered in oral capsule form. The CALM (Combination of YIV-906 and Sorafenib to treat Advanced Liver cancer in a Multi-center study) trial is a multi-regional, randomized, placebo-controlled study.
Phase-Based Estimates
1
Effectiveness
2
Safety
Nivolumab
for Carcinoma, Hepatocellular
Bethesda, MD
18+
All Sexes
Phase 2
Recruiting
Locally Advanced
Bethesda, MD
18+
All Sexes
Background: A most common liver cancer in adults is hepatocellular carcinoma. Other kinds of liver cancer happen when colorectal or pancreatic cancer spreads to the liver. Researchers want to study if a combination of drugs helps people with these cancers. The drugs are nivolumab, tadalafil, and vancomycin. Objective: To investigate if nivolumab given with tadalafil and vancomycin causes liver cancer to shrink. Eligibility: Adults ages 18 years and older with hepatocellular carcinoma or metastases to the liver from colorectal or pancreatic cancer for which standard treatment has not worked Design: Participants will be screened with: Medical and cancer history Review of symptoms and ability to perform normal activities Physical exam Heart test. Some participants may meet with a cardiologist and/or have another heart test. Scan of the chest, abdomen, and pelvis Blood and urine tests Tumor sample review. This can be from a previous procedure. Participants will receive the study drugs in 4-week cycles. In each cycle participants will: Get nivolumab through a small plastic tube in the arm on Day 1. Take tadalafil by mouth 1 time every day. Take vancomycin by mouth 4 times a day. They will take it every day for weeks 1 3, then not take it for week 4. Complete a medicine diary of dates, times, missed doses and symptoms. Throughout the study, participants will repeat screening tests and will give stool samples or rectal swabs. After their last cycle, participants will have 3 follow-up visits over 3 months. Then they will be contacted every 6 months by phone or email and asked about their general well-being. ...
Phase-Based Estimates
1
Effectiveness
2
Safety
68Gallium Citrate
for Carcinoma
Newark, NJ
18+
All Sexes
Phase 2
Waitlist Available
Newark, NJ
18+
All Sexes
The aim of the present study is to validate the uptake of novel, positron emitting radiotracer, 68Gallium Citrate in hepatocellular carcinoma(HCC). The investigators also aim to evaluate the sensitivity of 68Gallium (68Ga)-citrate positron emission tomography/computed tomography (PET/CT) for the identification of intrahepatic HCC lesions in comparison with existing modalities: computed tomography (CT) alone and magnetic resonance imaging (MRI). The investigators expect that 68Ga-citrate PET/CT will offer a sensitive functional imaging modality for identification of HCC lesions in the liver. The investigators intend to use the results of this preliminary study to fuel further studies in the utility of 68Ga-citrate PET/CT for HCC treatment monitoring.
Phase-Based Estimates
1
Effectiveness
2
Safety
Tremelimumab
for Carcinoma, Hepatocellular
Bethesda, MD
18+
All Sexes
Phase 2
Waitlist Available
Grade I
Bethesda, MD
18+
All Sexes
BACKGROUND: Various tumor ablative procedures and techniques have been shown to result in immunogenic cell death and induction of a peripheral immune response. The term ablative therapies applies to trans-arterial catheter chemoembolization (TACE), radiofrequency ablation (RFA) and cryoablation (CA). The underlying hypothesis of this study is that the effect of immune checkpoint inhibition can be enhanced by TACE, CA and RFA in patients with advanced hepatocellular carcinoma (HCC) and biliary tract carcinomas (BTC). We have already demonstrated proof of principle as well as safety and feasibility of this approach with anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) therapy. Based on the concept of programmed death-ligand 1 (PDL1)-mediated adaptive resistance and the emerging role of programmed cell death protein 1 (PD1) therapy in HCC, we would like to evaluate the combination of tremelimumab and durvalumab (with ablative therapies) in HCC and BTC. Objectives: - To preliminarily evaluate the 6-month progression free survival (PFS) of combining tremelimumab and durvalumab in patients with advanced HCC (either alone or with cryoablation, TACE or RFA) and in patients with advanced biliary tract carcinoma (BTC) (either alone or with cryoablation or RFA). ELIGIBILITY: Histologically or cytologically confirmed diagnosis of HCC or biliary tract carcinoma OR histopathological confirmation of carcinoma in the setting of clinical and radiological characteristics which, together with the pathology, are highly suggestive of a diagnosis of HCC (or biliary tract carcinoma). Childs-Pugh A/B7 cirrhosis only is allowed. If patient does not have cirrhosis, this limitation does not apply. Patients must have disease that is not amenable to potentially curative resection, radiofrequency ablation, or liver transplantation. DESIGN: We will evaluate the combination of tremelimumab and durvalumab (with ablative therapies) in cohorts A (HCC; N=40) and B (BTC; N=30). The first N=10 patients in both cohorts will receive tremelimumab and durvalumab only (i.e. No interventional radiologic procedures). A: Advanced HCC, BCLC# Stage B/C N= 1st 10 pts: No ablative procedure Cryoablation/RFA/TACE## Tremelimumab 75mg flat dose every (q)28 days for 4 doses; Durvalumab 1500mg flat dose q28 days until end of study (EOS)### 40 total: 10 trem+ dur alone; 10 trem+ dur + TACE; 10 trem + dur + RFA; 10 trem + dur + cryo B: Intra/extra-hepatic cholangiocarcinoma N= 1st 10 patients (pts): No ablative procedure; RFA/ cryoablation Tremelimumab 75mg flat dose q28 days for 4 doses; Durvalumab 1500mg flat dose q28 days until EOS### 30 total: 10 trem+ dur alone; 10 trem + dur + RFA; 10 trem BCLC = Barcelona clinic liver cancer staging system For BCLC stage B patients TACE may be repeated as per standard of care EOS = End of study treatment or meeting any of the off-treatment or off study criteria.
Phase-Based Estimates
2
Effectiveness
3
Safety
Nivolumab
for Carcinoma, Hepatocellular
San Antonio, TX
18+
All Sexes
Phase 3
Waitlist Available
Locally Advanced
San Antonio, TX
18+
All Sexes
This study is evaluating whether a drug or a surgery is more effective in the treatment of advanced hepatocellular carcinoma.
Phase-Based Estimates
1
Effectiveness
2
Safety
Durvalumab
for Carcinoma, Hepatocellular
New Haven, CT
18+
All Sexes
Phase 2
Waitlist Available
Locally Advanced
New Haven, CT
18+
All Sexes
This study is evaluating whether a drug called durvalumab or tremelimumab can be used to treat liver cancer.
Phase-Based Estimates
1
Effectiveness
2
Safety
SBRT
for Carcinoma, Hepatocellular
New York, NY
18+
All Sexes
Phase 2
Recruiting
1 Prior Treatment
New York, NY
18+
All Sexes
This study is evaluating whether a combination of two treatments may be more effective than either treatment alone for treating liver cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Best Supportive Care
for Carcinoma, Hepatocellular
Toronto, Canada
18+
All Sexes
Waitlist Available
High Risk
Toronto, Canada
18+
All Sexes
This study is evaluating whether one dose of palliative radiation therapy directed to the liver in combination with standard BSC might help to reduce liver pain/discomfort due to cancer when compared to getting standard BSC alone.
Phase-Based Estimates
1
Effectiveness
1
Safety
Adaptive Radiation Therapy
for Carcinoma, Hepatocellular
Ann Arbor, MI
18+
All Sexes
Waitlist Available
Ann Arbor, MI
18+
All Sexes
This study is evaluating whether a new type of radiation therapy may help improve the safety and efficacy of radiation therapy for liver cancer.
Phase-Based Estimates
1
Effectiveness
1
Safety
Vitamin D3 2000 IU
for Hepatocellular Carcinoma
New York, NY
18+